Opinion

Shock therapy to treat the Novel Coronavirus Disease (COVID-19) by ddNTPs

Yeping Tan*

Wuhan Jinyitai Biological Co., Ltd., Biolake, Wuhan 430073, Hubei Province, China

The Novel Coronavirus (SARS-CoV-2) has caused a massive global outbreak, presenting a significant public health emergency and international concern. Thousands of critically ill patients are dying daily. To date, there are no clinically approved antiviral drug available to cure the Novel Coronavirus infections. I highly recommend the clinical trial of 2’,3’-dideoxyribonucleoside triphosphate (ddNTPs, except ddTTP) to be used for the Novel Coronavirus Disease (COVID-19) antiviral therapy. The Coronavirus replication in vivo could be inhibited immediately by very low concentration of ddUTP that is based on the Sager DNA sequencing technique. Since the RNA of Coronavirus replication could be faster than host cells, ddUTP could give priority to virus rather than to host cells. Research and discussion of using concentration of ddUTP, time of ddUTP rejection, for the most severe cases are necessary to perform the clinic trial. Predictably, it should cause a toxic reaction to cells and organs in patients, even inducing patients' shake. Saving lives should be our utmost priority and it is necessary to process the valuable clinic trial immediately!

Copyright: © 2020 Tan Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.